SG11201809501PA - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide - Google Patents
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideInfo
- Publication number
- SG11201809501PA SG11201809501PA SG11201809501PA SG11201809501PA SG11201809501PA SG 11201809501P A SG11201809501P A SG 11201809501PA SG 11201809501P A SG11201809501P A SG 11201809501PA SG 11201809501P A SG11201809501P A SG 11201809501PA SG 11201809501P A SG11201809501P A SG 11201809501PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- chlorophenyl
- street
- pct
- san diego
- Prior art date
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 title abstract 2
- 201000005787 hematologic cancer Diseases 0.000 title abstract 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 title abstract 2
- PWBHUSLMHZLGRN-UHFFFAOYSA-N 2-(4-chlorophenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2,2-difluoroacetamide Chemical compound ClC1=CC=C(C=C1)C(C(=O)NCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)(F)F PWBHUSLMHZLGRN-UHFFFAOYSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101150015280 Cel gene Proteins 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346344P | 2016-06-06 | 2016-06-06 | |
| PCT/US2017/035892 WO2017214014A1 (en) | 2016-06-06 | 2017-06-05 | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809501PA true SG11201809501PA (en) | 2018-12-28 |
Family
ID=60482040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809501PA SG11201809501PA (en) | 2016-06-06 | 2017-06-05 | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10245258B2 (enExample) |
| EP (1) | EP3463358A4 (enExample) |
| JP (1) | JP7163281B2 (enExample) |
| KR (1) | KR20190015300A (enExample) |
| CN (2) | CN109414436A (enExample) |
| AU (2) | AU2017278114B2 (enExample) |
| BR (1) | BR112018075206A2 (enExample) |
| CA (1) | CA3026396A1 (enExample) |
| CL (1) | CL2018003499A1 (enExample) |
| EA (1) | EA201892746A1 (enExample) |
| IL (1) | IL262565B (enExample) |
| MX (1) | MX388717B (enExample) |
| SG (1) | SG11201809501PA (enExample) |
| WO (1) | WO2017214014A1 (enExample) |
| ZA (1) | ZA201807105B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| EP3399980B1 (en) * | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| US11535603B1 (en) | 2016-09-30 | 2022-12-27 | Deuterx, Llc | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same |
| DK3689868T3 (da) | 2016-12-01 | 2024-01-02 | Arvinas Operations Inc | Tetrahydronaphthalen- og tetrahydroisoquinolinderivater som østrogenreceptordegraderende midler |
| CN113347974A (zh) * | 2018-12-31 | 2021-09-03 | 细胞基因公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的组合物和使用方法 |
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| CN115607552B (zh) | 2019-10-21 | 2024-06-18 | 新基公司 | 取代的4-氨基异二氢吲哚-1,3-二酮化合物和第二种活性剂的组合用途 |
| MX2022005371A (es) | 2019-11-05 | 2022-08-04 | Celgene Corp | Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperi din-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. |
| MX2022006133A (es) | 2019-12-06 | 2022-06-17 | Celgene Corp | Procesos para preparar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin- 3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. |
| IL296557A (en) * | 2020-03-16 | 2022-11-01 | Celgene Corp | Combined treatment for acute myeloid leukemia |
| CN116390916A (zh) * | 2020-09-14 | 2023-07-04 | 阿尔维纳斯运营股份有限公司 | 用于靶向降解雌激素受体的化合物的结晶形式 |
| PE20230847A1 (es) | 2020-09-23 | 2023-05-23 | St Jude Childrens Res Hospital Inc | Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-il)arilsufonamida sustituidos como modulares de la proteina cereblon |
| KR20240066906A (ko) * | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA008072B1 (ru) * | 2001-12-03 | 2007-02-27 | Новацея, Инк. | Фармацевтические составы, содержащие соединения активного витамина d |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20090175869A1 (en) | 2007-05-31 | 2009-07-09 | Ascenta Therapeutics, Inc. | Pulsatile Dosing of Gossypol for Treatment of Disease |
| ES2363070T3 (es) | 2009-05-20 | 2011-07-19 | Hybrigenics | Nuevos usos terapéuticos de inecalcitol. |
| SG11201401946QA (en) | 2011-11-01 | 2014-05-29 | Celgene Corp | Methods for treating cancers using oral formulations of cytidine analogs |
| CA2926307C (en) * | 2013-12-05 | 2021-11-16 | F. Hoffmann-La Roche Ag | Novel combination treatment for acute myeloid leukemia (aml) |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| EP3399979B9 (en) * | 2016-01-08 | 2023-10-04 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| CN113662941A (zh) | 2016-01-08 | 2021-11-19 | 细胞基因公司 | 抗增殖化合物以及其药物组合物和用途 |
| CA3010794A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
-
2017
- 2017-06-05 IL IL262565A patent/IL262565B/en unknown
- 2017-06-05 WO PCT/US2017/035892 patent/WO2017214014A1/en not_active Ceased
- 2017-06-05 CN CN201780035323.6A patent/CN109414436A/zh active Pending
- 2017-06-05 CN CN202211003162.1A patent/CN115282149A/zh active Pending
- 2017-06-05 EP EP17810774.4A patent/EP3463358A4/en not_active Withdrawn
- 2017-06-05 SG SG11201809501PA patent/SG11201809501PA/en unknown
- 2017-06-05 MX MX2018015120A patent/MX388717B/es unknown
- 2017-06-05 BR BR112018075206-1A patent/BR112018075206A2/pt not_active Application Discontinuation
- 2017-06-05 EA EA201892746A patent/EA201892746A1/ru unknown
- 2017-06-05 AU AU2017278114A patent/AU2017278114B2/en active Active
- 2017-06-05 US US15/614,434 patent/US10245258B2/en active Active
- 2017-06-05 KR KR1020187035780A patent/KR20190015300A/ko not_active Ceased
- 2017-06-05 CA CA3026396A patent/CA3026396A1/en active Pending
- 2017-06-05 JP JP2019516086A patent/JP7163281B2/ja active Active
-
2018
- 2018-10-24 ZA ZA2018/07105A patent/ZA201807105B/en unknown
- 2018-12-06 CL CL2018003499A patent/CL2018003499A1/es unknown
-
2019
- 2019-02-13 US US16/275,234 patent/US20190175573A1/en not_active Abandoned
-
2020
- 2020-07-02 US US16/920,267 patent/US11590117B2/en active Active
-
2023
- 2023-01-25 US US18/101,499 patent/US20230158009A1/en not_active Abandoned
- 2023-04-06 AU AU2023202159A patent/AU2023202159A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109414436A (zh) | 2019-03-01 |
| AU2023202159A1 (en) | 2023-05-04 |
| US20210154182A1 (en) | 2021-05-27 |
| MX2018015120A (es) | 2019-04-15 |
| CA3026396A1 (en) | 2017-12-14 |
| JP2019517587A (ja) | 2019-06-24 |
| JP7163281B2 (ja) | 2022-10-31 |
| US20230158009A1 (en) | 2023-05-25 |
| EP3463358A4 (en) | 2020-07-22 |
| CN115282149A (zh) | 2022-11-04 |
| US10245258B2 (en) | 2019-04-02 |
| WO2017214014A1 (en) | 2017-12-14 |
| EP3463358A1 (en) | 2019-04-10 |
| BR112018075206A2 (pt) | 2019-03-19 |
| EA201892746A1 (ru) | 2019-06-28 |
| US20170348298A1 (en) | 2017-12-07 |
| KR20190015300A (ko) | 2019-02-13 |
| CL2018003499A1 (es) | 2019-03-15 |
| IL262565B (en) | 2022-08-01 |
| ZA201807105B (en) | 2020-01-29 |
| US20190175573A1 (en) | 2019-06-13 |
| AU2017278114B2 (en) | 2023-01-12 |
| US11590117B2 (en) | 2023-02-28 |
| AU2017278114A1 (en) | 2018-11-29 |
| IL262565A (en) | 2018-12-31 |
| MX388717B (es) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809501PA (en) | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201901937WA (en) | Pyridine compound | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201805777QA (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| SG11201908228TA (en) | Chemical compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| SG11201804100UA (en) | Pharmaceutical composition comprising a potent inhibitor of urat1 | |
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201810793XA (en) | Pharmaceutical combinations | |
| SG11201809031XA (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |